利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.064 秒)

    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY
    21.
    发明申请
    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开
    跨物种特异性单链单链单链抗体

    公开(公告)号：US20110275787A1

    公开(公告)日：2011-11-10

    申请号：US13122280

    申请日：2009-10-01

    申请人： Peter Kufer ,  Tobias Raum

    发明人： Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/18 ,  C07K14/435

    CPC分类号： C07K16/2863 ,  C07K16/2803 ,  C07K16/2878 ,  C07K16/2884 ,  C07K2317/31 ,  C07K2317/34

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

    摘要翻译： 本发明涉及双特异性单链抗体分子，其包含由能够结合人和非黑猩猩灵长类CD3ε链的表位的一个抗体可变结构域组成的第一结合结构域，其中所述表位是氨基酸序列的一部分 包括在由SEQ ID NOs组成的组中。 2,4,6和8以及能够结合人和非黑猩猩灵长类动物靶标抗原的表位的第二结合结构域。 本发明还涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3抗原表位的第一结合结构域; （ε）链，其中所述表位是包含在SEQ ID NO中的氨基酸序列的一部分。 2,4,6和8以及由能够与人的表位结合的一个抗体可变结构域和非黑猩猩灵长类动物靶标抗原组成的第二结合结构域。 本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。 本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

    Method of identifying binding site domains that retain the capacity of binding to an epitope
    22.
    发明授权
    Method of identifying binding site domains that retain the capacity of binding to an epitope 有权
    鉴定保留与表位结合的能力的结合位点结构域的方法

    公开(公告)号：US07435549B1

    公开(公告)日：2008-10-14

    申请号：US09554465

    申请日：1998-11-16

    申请人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    发明人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    IPC分类号： G01N33/53

    CPC分类号： C40B40/02 ,  A61K38/00 ,  C07K14/70525 ,  C07K14/70528 ,  C07K14/70532 ,  C07K16/3046 ,  C07K2319/00 ,  C12N15/1037

    摘要： The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further relates to a kit comprising components such as panels of recombinant vectors of bacterial libraries transfected with a panel of recombinant vectors which is useful in carrying out the method of the invention. Furthermore, binding site domains and fusion proteins obtainable by the method of the invention as well as antibody-like molecules comprising such domains and proteins are described. Furthermore, pharmaceutical and diagnostic compositions containing the above-described fusion proteins and polypeptides are provided.

    摘要翻译： 本发明涉及一种鉴定结合位点结构域的方法，当定位在重组双或多价多肽中的至少另一个结构域的C-末端时，其保留与表位结合的能力。 本发明还涉及一种试剂盒，其包含诸如用于实施本发明的方法的重组载体的一组重组载体转染的细菌文库的重组载体的片段的组分。 此外，描述了可通过本发明的方法获得的结合位点结构域和融合蛋白以及包含这种结构域和蛋白质的抗体样分子。 此外，提供含有上述融合蛋白和多肽的药物和诊断组合物。

    Human antibodies that bind human 17-A1/EpCAM tumor antigen
    26.
    发明授权
    Human antibodies that bind human 17-A1/EpCAM tumor antigen 失效
    结合人17-A1 / EpCAM肿瘤抗原的人抗体

    公开(公告)号：US07227002B1

    公开(公告)日：2007-06-05

    申请号：US09403107

    申请日：1998-04-14

    申请人： Peter Kufer ,  Tobias Raum

    发明人： Peter Kufer ,  Tobias Raum

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  C12P21/04 ,  C07H21/04

    CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K16/30 ,  C07K2317/34

    摘要： The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.

    摘要翻译： 本发明提供在人体中低或不是免疫原性的抗人抗体或其片段。 特别地，抗体或片段针对人肿瘤抗原，优选针对人肿瘤抗原17-1A，也称为EpCAM，EGP或GA 733-2。 还提供了包含上述抗体或其片段的药物组合物。

    Expression-enhanced polypeptides
    27.
    发明授权
    Expression-enhanced polypeptides 有权
    表达增强多肽

    公开(公告)号：US08518403B2

    公开(公告)日：2013-08-27

    申请号：US11572116

    申请日：2005-07-15

    申请人： Patrick Hoffmann ,  Silke Mittelstrass ,  Jens Hennecke ,  Tobias Raum

    发明人： Patrick Hoffmann ,  Silke Mittelstrass ,  Jens Hennecke ,  Tobias Raum

    IPC分类号： C12P21/04 ,  C12P21/08 ,  C12N15/00 ,  C12N15/62 ,  C12N15/64 ,  A61K39/395

    CPC分类号： C07K14/4705 ,  C07K16/00 ,  C07K2317/622 ,  C07K2319/00 ,  C12N15/62

    摘要： A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.

    摘要翻译： 复合多肽，所述复合多肽包含期望的多肽和表达增强结构域（“EED”），所述EED分别包含第一和第二半胱氨酸氨基酸残基Cys1和Cys2，Cys1位于更靠近复合物的N末端 多肽分子，其中Cys1和Cys2被多肽接头分离，所述连接体不含半胱氨酸和脯氨酸; - 限定足以允许Cys1和Cys2彼此参与分子内二硫键的长度; 并且具有在水溶液中基本上不含次级多肽结构的柔性多肽构象，其中Cys1和Cys2中的至少一个被衍生化部分衍生化。